During Thursday’s Current trade, Shares of Align Technology, Inc. (NASDAQ:ALGN), lost -0.35% to $62.33.
Align Technology, Inc. (ALGN) a dental-equipment maker, slid the most in more than four months after the U.S. Patent and Trademark Office rejected one of its patents for clear orthodontic braces and agreed to re-examine two others.
The shares fell 3.1 percent to $62.29 at the New York close, their biggest decline since January.
ClearCorrect LLC, one of Align’s competitors, said in a statement Wednesday that the patents were too similar to existing treatments, and it had asked the patent office to revisit them. It challenged four of Align’s patents in total and said it anticipates the patent office to re-examine the fourth as well. ClearCorrect had formerly been found to be infringing the same patents in a May 2013 International Trade Commission ruling. Of Align’s $198.1 million in first-quarter revenue, about 94 percent came from clear aligners, which straighten teeth with hard-to-see retainers instead of metal braces. The company has more than 350 patents in its portfolio, so it’s difficult to say whether losing just one is significant, Goldman Sachs analyst Robert Jones said in a note. Yet it could lead to concerns that its other patents aren’t stable.
Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) services for use in dentistry, orthodontics, and dental records storage in the United States and internationally.
Shares of WisdomTree Investments, Inc. (NASDAQ:WETF), declined -1.40% to $22.55, during its current trading session.
WisdomTree (WETF), an exchange-traded product (“ETP”) sponsor and asset manager, declared the launch of the WisdomTree International Hedged Equity Fund (HDWM), and the WisdomTree Barclays U.S. Aggregate Bond Improved Yield Fund (AGGY) on the NYSE Arca. HDWM seeks to provide exposure to dividend-paying companies in the developed world, not taking into account Canada and the United States, that pay regular cash dividends while neutralizing exposure to fluctuations of the foreign currencies relative to the U.S. dollar. AGGY seeks to provide broad exposure to the U.S. investment grade, fixed income securities market through the Barclays U.S. Aggregate Improved Yield Index while seeking to enhance yield within desired risk parameters and constraints. HDWM has an expense ratio of 0.35% and AGGY has a net expense ratio of 0.12%[1].
WisdomTree Investments, Inc., through its auxiliaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes.
Methanex Corporation (USA) (NASDAQ:MEOH), during its Thursday’s current trading session decreased -0.97% to $46.10.
Methanex Corporation (MEOH) declared that its Board of Directors has declared a quarterly dividend of US$0.275 per share that will be payable on September 30, 2015 to holders of common shares of record on September 16, 2015.
Methanex is a Vancouver-based, publicly traded company and is the world’s largest producer and supplier of methanol to major international markets. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol “MX” and on the NASDAQ Global Market in the United States under the trading symbol “MEOH”. Methanex can be visited online at www.methanex.com.
Methanex Corporation produces and supplies methanol in the Asia Pacific, North America, Europe, and South America. It also purchases methanol produced by others under methanol offtake contracts and on the spot market. The company was founded in 1968 and is headquartered in Vancouver, Canada.
Finally, Synthetic Biologics Inc (NYSEMKT:SYN), decreased -3.32%, to $3.20.
Synthetic Biologics, Inc. (SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, stated the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
